Healthcare / Medical DevicesTokyo
$1326.00
+16.00 (+1.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-232.1M · quality 58.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$18.3B
P/E
148.7x
↑EV/EBITDA
N/A
•ROE
6.6%
↑Gross Margin
97.2%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.6%
FCF CAGR
—
FCF margin
-133.5%
FCF / Net income
-1.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $132.7M · net income $113.4M · FCF $-177.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $132.7M | $132.7M | $194.2M | $100.5M | $139.3M |
| Net Income | $113.4M | $113.4M | $-258.3M | $-335.8M | $-254.3M |
| EBITDA | $-178.8M | $-178.8M | $-250.5M | $-332.5M | $-244.6M |
| EPS | 8.92 | 8.92 | -20.32 | -26.42 | -22.33 |
| Gross Margin | 97.2% | 97.2% | 85.3% | 99.8% | 58.1% |
| Operating Margin | -134.8% | -134.8% | -130.0% | -332.1% | -151.3% |
| Net Margin | 85.5% | 85.5% | -133.0% | -334.0% | -182.5% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.22 | 0.17 | 0.09 |
| Current Ratio | 19.46 | 19.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-177.1M | $-177.1M | $-232.1M | $-286.9M | $-231.7M |
| Returns | |||||
| ROE | 6.6% | 6.6% | -16.1% | -18.0% | -11.6% |
| Valuation | |||||
| P/E | 148.65 | 148.65 | — | — | — |
| P/B | 9.80 | 9.80 | 2.69 | 3.27 | 2.26 |
| Growth & Yield | |||||
| Revenue Growth | -31.7% | -31.7% | 93.1% | -27.8% | — |
| EPS Growth | 143.9% | 143.9% | 23.1% | -18.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
136.3%
EPS terminal req.
$117.66
Spread vs growth
7.6%
5Y implied EPS CAGR
74.0%
EPS terminal req.
$142.37
Spread vs growth
69.9%
10Y implied EPS CAGR
38.4%
EPS terminal req.
$229.29
Spread vs growth
105.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-20.32 → 8.92
Residual
-28.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.